Federal record
FDA Warning Letter issued February 20, 2026 · As of October 2026, Vial did not find a close-out letter in FDA records. Read the FDA letter →
We're providing this information based on regulatory filings Vial reviewed as of 2026-10-07. Regulatory status can change, and actions may be resolved or closed out. Confirm current status with the issuing agency: FDA.gov →
NewSelf
WY · Serves 50 states
Is this your company? Claim this profile.
NewSelf is a GLP-1 clinic available in all 50 states. The FDA issued a warning letter involving NewSelf on February 20, 2026, with no close-out letter found resolving it. Pricing was not publicly listed, so total cost should be confirmed before signing up.
What they offerWeight LossGLP-1
Why this score?
The Vial Score measures how much of this provider's public record Vial could confirm, and how clearly the provider discloses it. It does not measure quality of care.
| 85-100 | High Confidence |
| 70-84 | Well Documented |
| 50-69 | Limited Confidence |
| 0-49 | Flagged |
NewSelf scores 38, in the Flagged band. The score moves when the public record changes. For NewSelf, the item most likely to move it: Pricing.
Payment never changes a score.
3 of 5 checks complete. The remaining checks have not been run yet. Missing checks reduce how complete the profile is. They are not a finding by themselves.
Score history
- 38September 2026Record updated
- 70August 2026Record updated
- 65July 2026Vial scoring update
- 70June 2026Record updated
- 35June 2026Record updated
- 63June 2026Vial scoring update
What we found on NewSelf
We reviewed FDA enforcement records, OIG exclusions, DEA registration, and HIPAA breach records.
NewSelf is a telehealth platform offering medical weight loss services through remote consultations with board-certified physicians across all 50 states. The service provides prescription medications including semaglutide and tirzepatide compounds, with flat-rate monthly pricing regardless of dosage and fast shipping options available.
The FDA issued a warning letter involving NewSelf on February 20, 2026. We have not found a close-out letter resolving it as of our last check (October 7, 2026); read the details below before going further. The company serves all 50 states. We could not independently verify a third-party certification or accreditation as of October 2026.
Why this score: 3 of 5 checks complete. Each links to the public source it was verified against.
A check we haven’t completed yet is not a mark against this provider. It just means we’re still sourcing that record. The score reflects what we’ve confirmed so far, and updates as more checks come in.
Vial describes the record, not the provider. This is not a medical recommendation or endorsement. Last reviewed October 1, 2026.
Worth asking before you choose
Ask these before you sign up.
- 1What changed after the FDA warning letter?
- 2Has FDA issued a close-out letter?
- 3Are you operating as a 503A pharmacy or a 503B outsourcing facility?
- 4Which states are you licensed to ship to?
- 5Can you provide current state pharmacy license details?
See all 5 questionsShow fewer
Screenshot these or show your doctor: they’re the same questions Vial would ask.
Compare record details
Absolutely Thin has no federal action found; NewSelf has an FDA warning letter with no close-out letter found.
NewSelf scores 38, Absolutely Thin scores 77.
| NewSelf | Absolutely Thin | |
|---|---|---|
| Federal actions | Confirmed | None found |
| Vial Score | 38/100 | 77/100 |
| LegitScript certified | No | No |
| States served | Nationwide (50 states) | Nationwide (50 states) |
What Vial measures, and what we don’t
We evaluate public records: federal enforcement history, registrations, certifications, and how transparent a provider is about its clinicians, pharmacies, and pricing. We don’t score bedside manner, clinical outcomes, or customer satisfaction, and we don’t collect user reviews.
Treatments offered
Other GLP-1 providers in Vial
Other GLP-1 clinics in Vial’s directory. Open a profile, or compare side by side.
See 2 more alternativesShow fewer
Not sure where to start?Answer a few questions and we’ll narrow the directory to providers that fit.
Find your providerMore GLP-1 providers
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.